Download MendeleyDiscovery of Potent DYRK2 Inhibitors with High Selectivity, Great Solubility, and Excellent Safety Properties for the Treatment of Prostate Cancer.
Yuan, K., Shen, H., Zheng, M., Xia, F., Li, Q., Chen, W., Ji, M., Yang, H., Zhuang, X., Cai, Z., Min, W., Wang, X., Xiao, Y., Yang, P.(2023) J Med Chem 66: 4215-4230
- PubMed: 36800260
- DOI: https://doi.org/10.1021/acs.jmedchem.3c00106
- Primary Citation of Related Structures:
8HLT - PubMed Abstract:
Prostate cancer (PCa) is a common male cancer with high incidence and mortality, and hormonal therapy as the major treatment for PCa patients is troubled by the inevitable resistance that makes us identify novel targets for PCa. Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) was found to be an effective target for the treatment of PCa, but the research on its inhibitors is rather little. In this work, a potent DYRK2 inhibitor 43 (IC 50 = 0.6 nM) was acquired through virtual screening and structural optimization, which displayed high selectivity among 205 kinases; meanwhile, detailed interactions of 43 with DYRK2 were illustrated by the cocrystal. Furthermore, 43 possessed great water solubility (29.5 mg/mL), favorable safety properties (LD 50 > 10,000 mg/kg), and potent anti-PCa activities, which could be used as a potential candidate in further preclinical studies.
Organizational Affiliation:
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
